Severity of Psoriasis Linked to Increased Risk of Death
Penn Medicine News Sep 01, 2017
The study, which published in the Journal of Investigative Dermatology, is the first to link psoriasis severity to an increased risk of death using an objective measure of disease severity Â called Body Surface Area (BSA) Â rather than treatment patterns, such as whether or not a patient was receiving oral, injectable or phototherapy treatment for the condition. It finds patients with psoriasis on 10 percent or more of their body are at almost double the risk of death.
ÂItÂs well established that psoriasis is associated with an increased risk for other comorbidities like chronic kidney disease, diabetes, and cardiovascular disease, but we donÂt yet understand how the severity of psoriasis impacts future risk of major health problems,Â said the studyÂs senior author Joel M. Gelfand, MD MSCE, a professor of Dermatology and Epidemiology at Penn.
For this study, Gelfand and his team used a metric called Body Surface Area (BSA) Â literally a measurement of the percentage of the body covered by psoriasis. Using a database from the United Kingdom, they looked at 8,760 patients with psoriasis and 87,600 people without it. They sent surveys to the patientÂs general practitioners to determine the body surface area affected by psoriasis as this information is not routinely available in medical records. They then looked at the number of deaths in each group by person–years, a measure that combines the number of people with the amount of years of data on them in the database.
Gelfand and his team used an average follow–up time of about four years. In that time, there was an average of 6.39 deaths per 1,000 person years in patients with psoriasis on more than 10 percent of their bodies, compared to 3.24 deaths in patients without psoriasis. Even when researchers adjusted for other demographic factors, patients with a BSA greater than 10 percent were 1.79 times more likely to have died Â almost double Â than other people their age and gender who do not have the condition. This risk persisted even when controlling for other risk factors like smoking, obesity, and other major medical conditions.
ÂOther studies that have examined this question, including our own prior research, have looked at patients who were receiving treatment for psoriasis, which is not an objective measurement of severity, making it unclear to whom the prior studies apply,Â said the studyÂs lead author Megan H. Noe, MD, MPH, a dermatologist and post–doctoral research fellow in GelfandÂs laboratory. ÂBy using BSA, which we can evaluate in a patientÂs clinical visit, we can better understand which patients are at highest risk for future medical problems and need preventative care.Â
The researchers say more research is needed to better understand the specific causes of death in patients with extensive psoriasis and to see if and how treatment can impact the risk.
Sign-up to continue reading. It is free & takes less than 2 mins
45 lakhs+ doctors trust M3 globally
Free & unlimited access to original articles and quizzes
Secure: we never sell your data